Although AMPs for the treatment of septic arthritis have not received extensive investigation, preliminary studies with recombinant C-type Lectin Domain Family 3 Member A (CLEC3A), a cartilage-specific protein, have shown significant antimicrobial activity against E. coli, P. aeruginosa, and S. aureus. Here, CLEC3A is linked to bacterial arthritis.